The use of income-based deductibles is potentially problematic because there is extensive evidence, both from Canada and other countries, that out-of-pocket charges reduce drug use. [3] [4] [5] Further, we know that cost-related nonadherence remains a problem for many Canadians. 6 However, the specific impact of income-based deductibles remains less clear. For example, an analysis undertaken shortly after BC's income-based Fair PharmaCare Plan was implemented in 2003 suggested the plan did not alter populationlevel use of prescription drugs. 7 But the province's previous drug plan already included high deductibles for adults under 65 years of age; therefore, the study was not a clean test of deductibles versus no deductibles. Similarly, evidence from Manitoba suggested that income-based deductibles decreased the use of inhaled corticosteroids by children with asthma. 8 However, as with the BC study, the prior public drug plan in Manitoba included a deductible per family. 8 Further, we lack information on the health impact of deductibles: a recent systematic review on the health impacts of prescription drug coverage found no studies specifically on deductibles. 9 The uncertainty about the impact of income-based deductibles on drug use in Canada has led to a major debate on the role that RESEARCH Impact of income-based deductibles on drug use and health care utilization among older adults such deductibles should play in provincial drug plans. A recent report from the Institute for Research on Public Policy concluded that BC's Fair PharmaCare plan should not be emulated in other provinces, 10 whereas others, such as the CD Howe Institute, 11 have recommended the plan as a model policy for reforming Ontario's public drug plan. To help inform this debate, we studied the impact of the income-based deductibles in the Fair PharmaCare plan on drug and health care utilization among older adults.
Methods

Study context
British Columbia offers its residents public drug coverage through the Fair PharmaCare plan. The income-based deductible for an individual or family enrolled in the plan is determined annually on the basis of the Canada Revenue Agency-verified net household income reported 2 years previously. Notably, the BC government maintained more generous coverage levels (socalled "enhanced coverage") for individuals who were eligible for seniors' drug benefits when the new plan was introduced (i.e., those born in 1939 or earlier). 12 Other members of their household born after 1939 are also eligible. As shown in Figure 1 , there are no deductibles for these households if the net income is less than $30 000; members pay coinsurance of 25% of drug costs, to a maximum of 1.25% of household income. In contrast, individuals born after 1939 who live in households with a net income between $15 000 and $30 000 face a 2% household deductible, after which they pay coinsurance of 30% of drug costs, to a maximum of 3% of household income. We leveraged this artificial break at 1939 to estimate the impact of deductibles within this income band.
Data sources
We used 3 population-based data systems on health services utilization in the province between 2003 and 2015. First, we captured data on individual prescriptions, including drug information, total cost and the publicly paid portion, from the BC PharmaNet system, an administrative database of all drug dispensations in the province. 13 Second, we obtained information on fee-for-service physician consultations and expenditures through the Medical Services Plan billings data.
14 Finally, we obtained information on all hospital admissions and lengths of stay in days from the Discharge Abstract Database.
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Study population
Our study focused on a population-based open cohort of adults eligible for coverage under the PharmaCare plan during the study period. We included only adults registered for Fair PharmaCare, because household income data were not available for nonregistered residents of the province. We excluded people who received drug benefits through the federal government, because they would not have been subject to the same program rules.
Our unit of observation was the person-year. We created our cohort by including all person-years for individuals born in 1928 through 1939 whose reported household income was between $14 000 and $30 000 (and thus had no income-based deductible) and those born in 1940 through 1951 whose reported household income was between $15 000 and $30 000 (and thus had a 2% income-based deductible ranging from $300 to $600). Finally, because individuals younger than the oldest household member could receive enhanced coverage by virtue of living with someone born in 1939 or earlier, we limited our analysis to the oldest individual in each household unit.
Outcome measures
We studied the impact of income-based deductibles on 7 outcomes within the following 4 categories:
PharmaCare drug expenditure: We calculated the average amount paid by the PharmaCare program per person-year to estimate the impact of enhanced coverage on the availability and extent of public drug payment.
Prescription drug use and costs: We calculated the average prescription drug expenditure (both public and private), the average number of prescriptions dispensed and the number of unique medicines (based on level 7 Anatomical Therapeutic Chemical Classification codes) per person-year in our cohort.
Physician visits and costs: We calculated the average number of unique physician contacts and the average physician expenditure per person-year (adjusted for inflation using Statistics Canada's consumer price index). We considered multiple billings from a unique patient and physician combination in the same day to represent a single visit.
Hospital admissions and days:
We calculated the average number of days spent in hospital and average number of unique hospital admissions per person-year.
Statistical analysis
We used a regression discontinuity analysis, one of the strongest quasi-experimental research designs, to study the impact of deductibles on the above outcomes. 16, 17 This method leverages the quasi-random nature of the change in program design at the 1939 birth year to derive causal estimates of "real world" impacts. 18 Because individuals on either side of this threshold are likely similar in terms of other characteristics, any abrupt differences in their drug and health services utilization can be attributed to the effects of the plan design. Observations in years further from the threshold aid in estimating the overall age-related trend. The main assumption in such an analysis is that all potential confounders do not have abrupt changes across this threshold. To test this assumption on observed covariates, we also estimated regression discontinuity models on the proportion of women and average household size. Regression discontinuity designs have a long history in economics and are gaining popularity in the medical literature. 19, 20 To fit our statistical models, we first determined the average for each outcome across all person-years in our data set. Using these aggregate figures, we fit linear regression models that included 6 terms: (1) an intercept term, (2) an incrementing variable for each year from 1928 onward to capture the slope, (3) the square of this term to capture any nonlinear trends in the outcomes, (4) an indicator variable for post-1939 observations, (5) an incrementing variable to capture the post-1939 slope in the outcome and (6) the square of this post-1939 slope to capture nonlinear trends. Our measure of interest was variable 4, which would represent abrupt changes in the outcome across the 1939 threshold. We also fit models to give more weight to observations closer to the 1939 threshold, which gave substantively similar results (triangular kernel weights, not shown).
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Results
Cohort characteristics
After exclusions, our cohort consisted of 280 615 individuals who contributed 1 219 168 person-years of data (Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.161119/-/DC1), or an average of 4.3 years. The cohort had roughly equal numbers of women and men (139 751 women, 49.8%), and the average age of individuals in their first year in the cohort was 66.7 years. We found no discontinuity in either sex or household size at the 1939 threshold (p = 0.51 and p = 0.17, respectively).
Public drug coverage
We found that the income-based deductible imposed on Pharma Care enrollees born after 1939 led to a sharp reduction in the proportion receiving public drug plan benefits. Our estimates showed that the 1939 threshold led to a 28.6% decrease in person-years with 1 or more claims where the public plan paid a portion (95% confidence Interval [CI] −29.7% to −27.5%; p < 0.001; Appendix 2, available at www.cmaj.ca/lookup/suppl/ doi:10.1503/cmaj.161119/-/DC1). As shown in Figure 2 , the average annual PharmaCare expenditure dropped by $205.59 per person per year at the 1939 threshold (95% CI −$247.81 to −$163.37; p < 0.001), which represented a 27.5% reduction.
Prescription drug use and costs
Despite the change in PharmaCare benefits, we found this did not translate into differences across the threshold in our overall measures of prescription drug use. Figure 3 shows the lack of change in overall drug spending, including both public and private sources (estimate −$6.60, 95% CI −$67.08 to $53.88; p = 0.8). We also found no clinically meaningful or statistically significant change in either the average annual number of prescriptions (estimate 0.54, 95% CI −0.89 to 1.97; p = 0.4; Appendix 3, available at www.cmaj.ca/lookup/suppl/ doi:10.1503/cmaj.161119/-/DC1) or in the number of unique medicines (estimate −0.02, 95% CI −0. 13 
Physician visits and costs
We observed only small changes in physician use across the 1939 threshold. As shown in Figure 4 , we found no statistically significant change in the number of physician visits (estimate 0 
Hospital admissions and days
Our analysis found no meaningful changes in either the number of hospital admissions or the number of days spent in hospital. Figure 5 shows 
Interpretation
We found that the imposition of a modest deductible of 2% of household income, in addition to coinsurance, on households earning between $15 000 and $30 000 reduced public drug expenditures and the proportion of people who qualified for public subsidy. At the same time, it did not reduce any of our measures of overall drug use, nor did it appear to affect the use of other health services, aside from a small increase in physician expenditures that was not accompanied by a rise in physician visit numbers. Given the limitations of prior research in this area, we think this represents the strongest evidence to date on the impact of income-based deductibles on the community-dwelling population of older adults in Canada.
Our results suggest that adding a modest deductible of 2% of household income in plans already requiring copayments was not associated with unintended consequences related to increased use of nonpharmaceutical health care in the older population we studied. This finding differs from the results of other Canadian studies, which showed that increased drug cost-sharing reduced drug use and increased use of other health services in at-risk groups (e.g., those on social assistance). 3 These more vulnerable populations, including individuals on social assistance, those in long-term care facilities and people with a few specific health conditions, were not included in our analyses. One factor that may differ between these populations and the one we studied is the availability of private insurance, but data on the extent of retiree benefits in Canada are incomplete. Also, the scale of the deductible in question may also be a crucial factor in determining any impact on drug use. A recent study suggested that a different population -adults with cardiovascular-related chronic conditions spending at least 5% of their household income on drugswere at elevated risk of cost-related nonadherence, 22 whereas the deductible under review in our study was 2%.
Limitations
Although our study benefits from a strong quasi-experimental design, there are limitations worth noting. First, as with all regression discontinuity studies, we were able to estimate the impact of income-based deductibles only at the threshold, in this case for individuals born in 1939 and 1940. Thus, although our results likely extrapolate to other older adults, they may not apply to younger adults, children or specific vulnerable populations. Second, the PharmaNet database does not contain data on the presence or lack of private drug insurance, so we could not study the degree to which that factor might insulate individuals from the PharmaCare deductibles. However, we think it is unlikely that rates of private coverage would have shown a break in trend at the 1939 threshold.
Third, we could not assess whether some households were intentionally lowering their incomes to obtain deductible-free coverage. Given the small financial reward for such changes, however, we think this is unlikely.
Finally, because of the structure of the Fair PharmaCare income bands, the lower limit of household income in the nodeductible group was $14 000, as compared with $15 000 in the deductibles group. Although this represents only a 6.7% lower income at the extreme, it may have resulted in bias in our results.
Conclusion
In recent years, there has been substantial debate in Canada over the role that income-based deductibles should play in public drug coverage. Our study showed that a modest income-based deductible had a considerable impact on the extent of public subsidy for prescription drugs. However, it had only a trivial impact on overall access to medicines and use of other health services. Our findings do not diminish the importance of coverage for more vulnerable populations, but rather they may increase the options available to policy-makers when considering health care financing reforms.
